FACULTAD DE CIENCIAS BIOMÉDICAS Y DE LA SALUD
Facultad
University of California, San Francisco
San Francisco, Estados UnidosPublicaciones en colaboración con investigadores/as de University of California, San Francisco (37)
2023
-
Holistic Treatment Response: An International Expert Panel Definition and Criteria for a New Paradigm in the Assessment of Clinical Outcomes of Spinal Cord Stimulation
Neuromodulation, Vol. 26, Núm. 5, pp. 1015-1022
-
Impact of Long-Term Evoked Compound Action Potential Controlled Closed-Loop Spinal Cord Stimulation on Sleep Quality in Patients With Chronic Pain: An EVOKE Randomized Controlled Trial Study Subanalysis
Neuromodulation, Vol. 26, Núm. 5, pp. 1030-1038
-
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Breast Cancer Research, Vol. 25, Núm. 1
2022
-
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
Life science alliance, Vol. 5, Núm. 4
-
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial
JAMA Oncology, Vol. 8, Núm. 7, pp. 1047-1052
-
Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: an observational, multicohort, retrospective analysis
The Lancet Respiratory Medicine, Vol. 10, Núm. 4, pp. 367-377
2021
-
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581
-
Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism
American Journal of Human Genetics, Vol. 108, Núm. 6, pp. 1138-1150
-
Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained
Journal of Bone and Mineral Research, Vol. 36, Núm. 2, pp. 236-243
2020
-
Oncological care organisation during COVID-19 outbreak
ESMO Open, Vol. 5, Núm. 4
-
Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1
Breast Cancer Research and Treatment, Vol. 184, Núm. 1, pp. 161-172
-
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 8, pp. 672-682
2019
-
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases
Future Oncology, Vol. 15, Núm. 19, pp. 2211-2225
-
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Journal of Bone and Mineral Research, Vol. 34, Núm. 4, pp. 632-642
-
Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita
Human Mutation, Vol. 40, Núm. 12, pp. 2270-2285
-
Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Journal of Bone and Mineral Research
2018
-
Change in topoisomerase 1–positive circulating tumor cells affects overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol
Clinical Cancer Research, Vol. 24, Núm. 14, pp. 3348-3357
-
Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course 06 Biological Sciences 0604 Genetics 11 Medical and Health Sciences 1109 Neurosciences
Journal of Neuroinflammation, Vol. 15, Núm. 1
2017
-
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication
Heart Rhythm, Vol. 14, Núm. 1, pp. e3-e40
-
Erratum to: Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial (Breast Cancer Research and Treatment, (2017), 165, 2, (329-341), 10.1007/s10549-017-4304-7)
Breast Cancer Research and Treatment